Table 4.

Breast Sensitivity

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit+)
POST OP	Overall Breast Sensitivity (N=320)	132 (41.3%)	146 (45.6%)	33 (10.3%)	9 (2.8%)
	Vs Arm (N=320)					0.126	0.447
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=66)	20 (30.3%)	38 (57.6%)	6 (9.1%)	2 (3.0%)
	AC (Doxorubicin and Cyclophosphamide) (N=99)	43 (43.4%)	46 (46.5%)	9 (9.1%)	1 (1.0%)
	Capecitabine (N=155)	69 (44.5%)	62 (40.0%)	18 (11.6%)	6 (3.9%)
	Vs Most Extensive Surgery (N=318)					0.176	0.530
	Breast Conserving Surgery (N=143)	53 (37.1%)	73 (51.0%)	14 (9.8%)	3 (2.1%)
	Full Mastectomy (N=175)	78 (44.6%)	72 (41.1%)	19 (10.9%)	6 (3.4%)
	Vs Axillary Dissection (N=320)					0.081	0.062
	No (N=65)	33 (50.8%)	28 (43.1%)	3 (4.6%)	1 (1.5%)
	Yes (N=255)	99 (38.8%)	118 (46.3%)	30 (11.8%)	8 (3.1%)
	Vs RT (N=300)					0.019	0.051
	No (N=139)	67 (48.2%)	60 (43.2%)	9 (6.5%)	3 (2.2%)
	Yes (N=161)	56 (34.8%)	79 (49.1%)	22 (13.7%)	4 (2.5%)
	Vs Number of Nodes Examined (N=313)					0.137	0.424
	0-3 (N=49)	23 (46.9%)	21 (42.9%)	4 (8.2%)	1 (2.0%)
	4-7 (N=53)	27 (50.9%)	21 (39.6%)	3 (5.7%)	2 (3.8%)
	8+ (N=211)	79 (37.4%)	100 (47.4%)	26 (12.3%)	6 (2.8%)
AT 12 MONTHS	Overall Breast Sensitivity (N=258)	154 (59.7%)	90 (34.9%)	11 (4.3%)	3 (1.2%)
	Vs Arm (N=258)					0.014	0.343
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	24 (44.4%)	26 (48.2%)	2 (3.7%)	2 (3.7%)
	AC (Doxorubicin and Cyclophosphamide) (N=82)	57 (69.5%)	23 (28.1%)	2 (2.4%)	0 (0%)
	Capecitabine (N=122)	73 (59.8%)	41 (33.6%)	7 (5.7%)	1 (0.8%)
	Vs Most Extensive Surgery (N=256)					<0.001	0.440
	Breast Conserving Surgery (N=117)	57 (48.7%)	55 (47.0%)	4 (3.4%)	1 (0.9%)
	Full Mastectomy (N=139)	96 (69.1%)	34 (24.5%)	7 (5.0%)	2 (1.4%)
	Vs Axillary Dissection (N=258)					0.043	0.043
	No (N=56)	40 (71.4%)	16 (28.6%)	0 (0%)	0 (0%)
	Yes (N=202)	114 (56.4%)	74 (36.6%)	11 (5.4%)	3 (1.5%)
	Vs RT (N=244)					<0.001	0.643
	No (N=109)	84 (77.1%)	20 (18.3%)	5 (4.6%)	0 (0%)
	Yes (N=135)	61 (45.2%)	66 (48.9%)	5 (3.7%)	3 (2.2%)
	Vs Number of Nodes Examined (N=253)					0.725	0.201
	0-3 (N=44)	27 (61.4%)	17 (38.6%)	0 (0%)	0 (0%)
	4-7 (N=39)	25 (64.1%)	11 (28.2%)	1 (2.6%)	2 (5.1%)
	8+ (N=170)	98 (57.6%)	61 (35.9%)	10 (5.9%)	1 (0.6%)
AT 24 MONTHS	Overall Breast Sensitivity (N=239)	166 (69.5%)	62 (25.9%)	8 (3.3%)	3 (1.3%)
	Vs Arm (N=239)					0.140	0.724
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	32 (65.3%)	15 (30.6%)	1 (2.0%)	1 (2.0%)
	AC (Doxorubicin and Cyclophosphamide) (N=82)	52 (63.4%)	25 (30.5%)	3 (3.7%)	2 (2.4%)
	Capecitabine (N=108)	82 (75.9%)	22 (20.4%)	4 (3.7%)	0 (0%)
	Vs Most Extensive Surgery (N=237)					0.320	0.103
	Breast Conserving Surgery (N=107)	78 (72.9%)	27 (25.2%)	2 (1.9%)	0 (0%)
	Full Mastectomy (N=130)	87 (66.9%)	35 (26.9%)	5 (3.8%)	3 (2.3%)
	Vs Axillary Dissection (N=239)					0.003	0.077
	No (N=51)	44 (86.3%)	7 (13.7%)	0 (0%)	0 (0%)
	Yes (N=188)	122 (64.9%)	55 (29.3%)	8 (4.3%)	3 (1.6%)
	Vs RT (N=225)					0.347	0.494
	No (N=100)	73 (73.0%)	24 (24.0%)	3 (3.0%)	0 (0%)
	Yes (N=125)	84 (67.2%)	365(28.0%)	3 (2.4%)	3 (2.4%)
	Vs Number of Nodes Examined (N=235)					0.293	0.756
	0-3 (N=41)	29 (70.7%)	11 (26.8%)	1 (2.4%)	0 (0%)
	4-7 (N=38)	30 (79.0%)	6 (15.8%)	1 (2.6%)	1 (2.6%)
	8+ (N=156)	103 (66.0%)	45 (28.9%)	6 (3.8%)	2 (1.3%)